Literature DB >> 6403411

Corneal epithelial dysplasia after trifluridine use.

P C Maudgal, B Van Damme, L Missotten.   

Abstract

Prolonged topical trifluridine treatment of herpes simplex keratitis in three elderly patients produced slightly raised dysplastic corneal epithelial lesions. The involved epithelium had a ground-glass appearance and exhibited opaque cells, edema, and spindle-shaped surface cells. Histopathology demonstrated severe cellular atypism, loss of cell polarity, dyskeratosis, parakeratosis, and a few mitotic figures. The pathological change was apparently intraepithelial. After scraping, the edema and opaque cells in the regenerated epithelium gradually disappeared in 3-4 months on cessation of trifluridine therapy. In one patient recurrence of dendritic keratitis, 5 weeks after scraping, was treated by topical bromovinyldeoxyuridine eye drops. Since severe epithelial dysplasia may represent a precancerous condition, prolonged use of trifluridine should be avoided.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6403411     DOI: 10.1007/BF02307009

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  38 in total

1.  Relative mutagenicity of nucleoside virostatic drugs in Chinese hamster ovary cells.

Authors:  P M Aebersold
Journal:  Adv Ophthalmol       Date:  1979

2.  Growth inhibition of cells in cultures and of vaccinia virus infected HeLa cells by derivatives of trifluorothymidine.

Authors:  J R Parkhurst; P V Danenberg; C Heidelberger
Journal:  Chemotherapy       Date:  1976       Impact factor: 2.544

3.  Histopathology and histochemistry of the superficial corneal epithelium in experimental herpes simplex keratitis.

Authors:  P C Maudgal; L Missotten
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1979-02-08

4.  Oral and topical treatment of experimental herpes simplex iritis with bromovinyldeoxyuridine.

Authors:  P C Maudgal; W Uyttebroeck; E De Clercq; L Missotten
Journal:  Arch Ophthalmol       Date:  1982-08

5.  Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster.

Authors:  E de Clercq; H Degreef; J Wildiers; G de Jonge; A Drochmans; J Descamps; P de Somer
Journal:  Br Med J       Date:  1980-11-01

6.  Oncogenic transformation of C3H/10T1/2 clone 8 mouse embryo cells by halogenated pyrimidine nucleosides.

Authors:  P A Jones; W F Benedict; M S Baker; S Mondal; U Rapp; C Heidelberger
Journal:  Cancer Res       Date:  1976-01       Impact factor: 12.701

7.  (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent.

Authors:  E De Clercq; J Descamps; P De Somer; P J Barr; A S Jones; R T Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

8.  Clinical evaluation of adenine arabinoside and trifluorothymidine in the treatment of corneal ulcers caused by herpes simplex virus.

Authors:  D J Coster; J R McKinnon; J I McGill; B R Jones; F T Fraunfelder
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

9.  Histopathology of human superficial herpes simplex keratitis.

Authors:  P C Maudgal; L Missotten
Journal:  Br J Ophthalmol       Date:  1978-01       Impact factor: 4.638

10.  Efficacy of (E)-5-(2-bromovinyl)-2'-deoxyuridine in the topical treatment of herpes simplex keratitis.

Authors:  P C Maudgal; L Missotten; E De Clercq; J Descamps; E De Meuter
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1981
View more
  9 in total

1.  Beta radiation of recurrent corneal intraepithelial neoplasia.

Authors:  D B Jones; K R Wilhelmus; R L Font
Journal:  Trans Am Ophthalmol Soc       Date:  1991

Review 2.  Pathological processes activated by herpes simplex virus-1 (HSV-1) infection in the cornea.

Authors:  Lulia Koujah; Rahul K Suryawanshi; Deepak Shukla
Journal:  Cell Mol Life Sci       Date:  2018-10-16       Impact factor: 9.261

3.  Topical Chemotherapy for Treating Ocular Surface Squamous Neoplasia with a Combination of Interferon α-2b and 5-Fluorouracil.

Authors:  Wen Geng; Jia-Song Wang; Bing-Jie Shi; Hua-Tao Xie; Ming-Chang Zhang
Journal:  Ophthalmol Ther       Date:  2022-06-15

4.  Bacterial Pigment Prodigiosin Demonstrates a Unique Antiherpesvirus Activity That Is Mediated through Inhibition of Prosurvival Signal Transducers.

Authors:  Rahul K Suryawanshi; Lulia Koujah; Chandrashekhar D Patil; Joshua M Ames; Alex Agelidis; Tejabhiram Yadavalli; Satish V Patil; Deepak Shukla
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

5.  Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes.

Authors:  Joseph Colin
Journal:  Clin Ophthalmol       Date:  2007-12

6.  BX795 demonstrates potent antiviral benefits against herpes simplex Virus-1 infection of human cell lines.

Authors:  Aqsa Iqbal; Rahul Suryawanshi; Tejabhiram Yadavalli; Ipsita Volety; Deepak Shukla
Journal:  Antiviral Res       Date:  2020-05-05       Impact factor: 5.970

7.  Acute Herpetic Keratitis: What is the Role for Ganciclovir Ophthalmic Gel?

Authors:  Afsun Sahin; Pedram Hamrah
Journal:  Ophthalmol Eye Dis       Date:  2012-04-19

Review 8.  Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications.

Authors:  Timothy Y Chou; Bennett Y Hong
Journal:  Ther Clin Risk Manag       Date:  2014-08-20       Impact factor: 2.423

Review 9.  Adoption of Innovation in Herpes Simplex Virus Keratitis.

Authors:  James Chodosh; Lawson Ung
Journal:  Cornea       Date:  2020-11       Impact factor: 3.152

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.